Stock data
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) reported revenue of US$0.00M and net income of -US$359.64M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.00M | — | -US$393.34M | -US$359.64M | — |
| 2024 | US$0.00M | — | -US$150.92M | -US$109.96M | — |
| 2023 | US$0.00M | — | -US$100.83M | -US$85.89M | — |
| 2022 | US$0.00M | — | -US$70.36M | -US$68.87M | — |
| 2021 | US$0.00M | — | -US$55.68M | -US$54.99M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$128.02M | — |
| 2026-03-31 | US$0.00M | -US$158.32M | — |
| 2025-12-31 | US$0.00M | -US$157.66M | — |
| 2025-09-30 | US$0.00M | -US$90.79M | — |
| 2025-06-30 | US$0.00M | -US$65.56M | — |
| 2025-03-31 | US$0.00M | -US$45.63M | — |
| 2024-12-31 | US$0.00M | -US$35.42M | — |
| 2024-09-30 | US$0.00M | -US$24.94M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.